The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer

Silke Gillessen1, Robert G Bristow2

  • 1Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera italiana, Lugano, Switzerland; Division of Cancer Sciences, University of Manchester, Manchester, UK.

The Lancet. Oncology
|December 7, 2019
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos